Adagene Reports Promising Responses for Muzastotug in Combination with Pembrolizumab
I'm PortAI, I can summarize articles.
Adagene Inc. announced promising responses for its anti-CTLA-4 therapy, muzastotug, in combination with pembrolizumab for MSS colorectal cancer. The therapy received FDA Fast Track Designation, indicating potential to improve patient survival and quality of life. Updated Phase 1b/2 clinical data will be shared soon, progressing towards a Phase 3 trial focusing on overall survival.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments